OptiNose's (OPTN) "Neutral" Rating Reaffirmed at HC Wainwright

OptiNose (NASDAQ:OPTN - Get Free Report)'s stock had its "neutral" rating reissued by HC Wainwright in a report issued on Monday,Benzinga reports. They presently have a $9.00 price target on the stock. HC Wainwright's target price would indicate a potential downside of 6.25% from the company's current price. HC Wainwright also issued estimates for OptiNose's Q2 2025 earnings at ($0.75) EPS, Q3 2025 earnings at ($0.96) EPS, Q4 2025 earnings at ($1.14) EPS, FY2026 earnings at ($2.91) EPS, FY2027 earnings at ($1.72) EPS, FY2028 earnings at ($0.21) EPS and FY2029 earnings at $1.01 EPS.

A number of other research firms have also recently weighed in on OPTN. Piper Sandler reaffirmed a "neutral" rating and set a $9.00 target price (down previously from $15.00) on shares of OptiNose in a research note on Friday, March 21st. Lake Street Capital cut shares of OptiNose from a "buy" rating to a "hold" rating and decreased their target price for the stock from $17.00 to $9.00 in a research note on Thursday, March 20th.

OptiNose Stock Performance

NASDAQ:OPTN remained flat at $9.60 during mid-day trading on Monday. The business has a 50 day moving average of $9.13 and a 200-day moving average of $7.44. The firm has a market capitalization of $97.22 million, a price-to-earnings ratio of -2.29 and a beta of -0.88. OptiNose has a 52 week low of $4.82 and a 52 week high of $20.03.

OptiNose (NASDAQ:OPTN - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($1.01) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.74) by ($0.27). The company had revenue of $18.51 million for the quarter, compared to analyst estimates of $17.70 million. As a group, research analysts predict that OptiNose will post -3.22 EPS for the current fiscal year.

Insider Transactions at OptiNose

In other news, CEO Ramy A. Mahmoud sold 6,376 shares of OptiNose stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $5.29, for a total transaction of $33,729.04. Following the transaction, the chief executive officer now owns 126,931 shares in the company, valued at approximately $671,464.99. The trade was a 4.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last 90 days, insiders have sold 8,213 shares of company stock worth $43,643. Company insiders own 2.30% of the company's stock.

Hedge Funds Weigh In On OptiNose

A number of hedge funds have recently modified their holdings of the business. Stonepine Capital Management LLC lifted its holdings in shares of OptiNose by 34.0% during the first quarter. Stonepine Capital Management LLC now owns 788,647 shares of the company's stock worth $7,232,000 after purchasing an additional 199,990 shares during the period. Acorn Capital Advisors LLC acquired a new position in OptiNose in the fourth quarter valued at $2,824,000. Groupe la Francaise acquired a new position in OptiNose in the first quarter valued at $1,898,000. Easterly Investment Partners LLC lifted its holdings in OptiNose by 235.7% in the first quarter. Easterly Investment Partners LLC now owns 156,666 shares of the company's stock valued at $1,437,000 after buying an additional 109,999 shares during the period. Finally, Gabelli Funds LLC acquired a new position in OptiNose in the first quarter valued at $734,000. Institutional investors and hedge funds own 85.60% of the company's stock.

About OptiNose

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.